

**PROHAPTENS
ARE NOT A
NEW IDEA!**




WHAT IDENTIFIES A CHEMICAL SENSITISER AS A PROHAPTEN

- Evidence/opinion that it is not a direct (re)acting chemical, i.e. an electrophile
- Evidence/opinion that is not susceptible to air oxidation to produce an electrophilic species
- Comparison with known activation systems, e.g. carcinogens, typically based on liver metabolism data
- An absence of any other explanation for its action

Characterisation of a contact allergen as a “prohaptten” is a “diagnosis of exclusion”

? HOW MANY PROHAPTENS?

- We used to suggest 30% (ACD: Chemical and Metabolic Mechanisms, Smith and Hotchkiss, 2001)
- Increasing evidence of the relative importance of air oxidation lowers this figure substantially (e.g. work on geraniol from Karlberg and colleagues)
- Also, the evidence that some supposed “prohaptens” are positive in reactivity tests forces us to rethink
- Perhaps 10% is closer to our current view of reality...



IN VIVO PREDICTIVE TESTS

- In the guinea pig methods, it was simply assumed that the animal was a good model – the only real debate was on test sensitivity.
- With the mouse (LLNA), validation demonstrated that predictivity for the human hazard was acceptable (about 85%), but again no specific consideration was applied regarding metabolic differences.
- Both species did detect many substances believed not to be direct acting haptens.

THE QUESTION I ASKED
ORIGINALLY AND STILL ASK TODAY
IS "WHAT DO WE KNOW ABOUT THE
REALITY IN MAN, AND HOW CAN
WE INVESTIGATE THE TOPIC?"

ORIGINALLY, MY IMPRESSION WAS
THAT **ALL** OF OUR APPARENT
KNOWLEDGE WAS BASED ALMOST
ENTIRELY ON CHEMICAL THEORY.

WHAT IS THE CURRENT STATUS?

- A PubMed search in early 2015 for "prohaptens and skin" yields only 25 hits; add "metabolism" and it falls to just 21
- Of these, just 2 involve research on which enzymes are involved in murine/human skin (in)activation of prohaptens
- Enzymes implicated: NADPH-dependent reductase and N-acetyl transferase
- NAT role is supported by work in 2009 from Blomeke and colleagues on NAT1 and 2 genotypes (fast versus slow)

WHAT IS THE CURRENT STATUS?

- Other searching yields these:


So, we have now a much better knowledge of the metabolic capabilities of skin, but that does not tell us which (pro)haptens are activated, nor how!

E, Landsiedel N, Fritsche E, with a 3D alternatives for 2: 21: 358-363.


HF, Krutmann E. Xenobiotic 3D-epidermis ves for 364-369.

RJ. Elucidation models by

CROSS REACTIONS: WHAT CAN WE LEARN?

- **Cinnamal and cinnamic alcohol: positivity to both could be concomitant contact allergy...but the common failure to react to both is important**
 - **...but very few dual positives to eugenol and isoeugenol occur, suggesting these do not share a common in vivo hapten**
- 

PROHAPTENS - THE OPPORTUNITY



We should focus on deriving the information that is needed, not on what we can generate easily!

Considering in vivo and in vitro tests,, one might ask whether a confirmatory HRIPT is the only way to be sure that a prohaptan has not been missed prior to consumer use/dermatologist feedback.